Author:
Wickström Malin,Haglund Caroline,Lindman Henrik,Nygren Peter,Larsson Rolf,Gullbo Joachim
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference37 articles.
1. Furner RL, Brown RK (1980) L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64:559–74
2. Teicher BA (1997) (405–418) Antitumor alkylating agents. In: De Vita Hellman Rodenberg VTSSA (ed) Cancer principals and practice of oncology. Lippincott-Raven, Philadelphia, USA
3. Jones RB (2002) Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res 112:305–322
4. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC Jr, Gajewski JL, Champlin RE (2001) High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82:420–426
5. Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H (2003) High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplant 31:755–761
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献